Carregant...
Preclinical study of a new (177)Lu-labeled somatostatin receptor antagonist in HT-29 human colorectal cancer cells
OBJECTIVE(S): Somatostatin receptor-positive neuroendocrine tumors have been targeted using various peptide analogs radiolabeled with therapeutic radionuclides for years. The better biomedical properties of radioantagonists as higher tumor uptake make these radioligands more attractive than agonists...
Guardat en:
| Publicat a: | Asia Ocean J Nucl Med Biol |
|---|---|
| Autors principals: | , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Mashhad University of Medical Sciences
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7354249/ https://ncbi.nlm.nih.gov/pubmed/32714998 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.22038/AOJNMB.2020.44432.1299 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|